CareDx (CDNA) is a Great Momentum Stock: Should You Buy?

Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Aug 27, 2026

Zacks Industry Outlook CareDx, BrightSpring and PACS

CareDx, BrightSpring and PACS have been highlighted in this Industry Outlook article.

Zacks Investment Research • Aug 25, 2026

3 Medical Service Stocks Resilient Amid Persistent Workforce Shortage

CareDx, BrightSpring and PACS Group are positioned for growth as digital health expands and workforce shortages reshape medical services.

Zacks Investment Research • Aug 24, 2026

5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns

Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.

Zacks Investment Research • Aug 18, 2026

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On August 5, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an aggregate of 97,090 shares of common stock. With respect to 34 of the new employees, an aggregate of 93,090 of the RSUs will vest o.

Business Wire • Aug 7, 2026

Why CareDx Stock Jumped Today

CareDx is helping to improve outcomes for transplant patients. The health monitor's non-invasive tests are in high demand.

The Motley Fool • Jul 31, 2026

CareDx Q2 Earnings Call Highlights

CareDx NASDAQ: CDNA reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integrating the recently acquired NavDx specialty oncology platform.

MarketBeat • Jul 30, 2026

CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript

CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 31, 2026

CareDx Announces Second Quarter 2026 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Revenue of $132 million, an increase of 52% year-over-year Testing Services revenue of $100 million, an increase of 61% year-over-year, and Testing Services volume of approximately 58,000, an increase of 17% year-o.

Business Wire • Jul 30, 2026

CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates

CareDx (CDNA) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.1 per share a year ago.

Zacks Investment Research • Jul 30, 2026